JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Accueil・Liste d'Actions・ADMA Biologics Inc
Search

ADMA Biologics Inc

Fermé

SecteurSoins de santé

10.5 2.74

Achat

Actualisation du prix 1 mai 2026, 19:59 UTC

AcheterVendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.41

Max

10.56

Chiffres clés

By Trading Economics

Revenu

13M

49M

Ventes

4.9M

139M

P/E

Moyenne du Secteur

18.217

67.147

BPA

0.216

Marge bénéficiaire

35.483

Employés

640

EBITDA

14M

65M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+142.48% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.3B

2.5B

Ouverture précédente

7.76

Clôture précédente

10.5

Sentiment de l'Actualité

By Acuity

58%

42%

299 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

N/A / 23.5406 Support & Résistance

ADMA Biologics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mai 2026, 22:17 UTC

Résultats

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Lire

4 mai 2026, 23:47 UTC

Résultats

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Lire

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Lire

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Lire

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Lire

4 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Lire

4 mai 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Lire

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Lire

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Lire

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Lire

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Shareholders to Own About 51% of Combined Company

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Deal Unanimously Recommended by Vault Board

DJ

Lire

4 mai 2026, 22:39 UTC

Acquisitions, Fusions, Rachats

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Lire

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Lire

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Lire

4 mai 2026, 22:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Lire

4 mai 2026, 22:26 UTC

Résultats
Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Lire

4 mai 2026, 22:02 UTC

Résultats

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Lire

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Lire

4 mai 2026, 21:52 UTC

Résultats

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Lire

4 mai 2026, 21:50 UTC

Résultats

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Lire

4 mai 2026, 21:50 UTC

Résultats

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Lire

4 mai 2026, 21:49 UTC

Résultats

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Lire

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Lire

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Lire

4 mai 2026, 21:43 UTC

Résultats

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Lire

4 mai 2026, 21:41 UTC

Résultats

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Lire

4 mai 2026, 21:40 UTC

Résultats

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Lire

Comparaison

Variation de prix

ADMA Biologics Inc prévision

Objectif de Prix

By TipRanks

142.48% hausse

Prévisions sur 12 Mois

Moyen 25 USD  142.48%

Haut 30 USD

Bas 21 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

N/A / 23.5406Support & Résistance

Court Terme

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Moyen Terme

Strong Bullish Evidence

All events are bullish.

Long Terme

Weak Bullish Evidence

There is one bullish event.

Sentiment

By Acuity

299 / 347Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Autres valeurs du secteur

JNJ

Johnson and Johnson

225.57

↑ +0.63%

UNH

UnitedHealth Group Inc

363.82

↓-1.87%

TMO

Thermo Fisher Scientific Inc

466.62

↑ +0.92%

ISRG

Intuitive Surgical Inc

451.55

↓-0.21%

ABT

Abbott Laboratories

87.15

↓-0.47%
help-icon Live chat